Our data suggest that therapeutic targeting of immune cell recruitment via the CXCL9– CXCL10–CXCL11/CXCR3 axis may be a valuable therapeutic strategy for resolution of inflammation in severe COVID-19, where it has become uncoupled from viral clearance. The gene discussed is CXCR3; the disease is COVID-19.